New Guidelines for Treating Osteoporosis
A physicians’ group has recommended new guidelines that doctors treat women who have osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent.
The new guidelines, from the American College of Physicians (ACP), were published in the Annals of Internal Medicine, according to a news release from the ACP.
ACP’s previous recommendations for treating low bone density and osteoporosis to prevent fractures were published in 2008. ACP’s 2017 guidelines presents additional available evidence on treatments, including new medications and biologic agents, to prevent fractures in men and women with low bone density or osteoporosis since publication of the 2008 guidelines.
“Physicians should prescribe generic drugs to treat patients with osteoporosis whenever possible and they should discuss the importance of medication adherence, especially for bisphosphonates,” Jack Ende, MD, MACP, president, ACP, said in the news release outlining the 2017 guidelines.
The ACP also said that the American Academy of Family Physicians had endorsed the guidelines.
Osteoporosis is a systemic skeletal disease characterized by decreasing bone mass and deterioration of bone tissue that leads to an increased risk for bone fragility and fracture, especially in the hip, spine, and wrist. An estimated 54 million men and women in the United States have low bone density or osteoporosis. About 50 percent of Americans older than 50 are at risk for osteoporotic fracture.
ACP’s guidelines focuses on the comparative benefits and risks of short- and long-term drug treatments for low bone density or osteoporosis, including prescriptions, calcium, vitamin D, and estrogen.
The evidence suggests that physicians should treat women with osteoporosis with drug therapy for five years. Continuing treatment after the initial five years may be beneficial for some patients and may be appropriate after reassessing the risks and benefits of continuing therapy, according to the news release.
ACP recommends against bone density monitoring during the five-year treatment period because the evidence does not show any benefit for monitoring during treatment. ACP also recommends against using menopausal estrogen therapy or menopausal estrogen plus progestin therapy or raloxifene for the treatment of osteoporosis in women. Estrogen treatment is associated with serious harms such as increased risk for cerebrovascular accidents and venous thromboembolic events that outweigh the potential benefits.
Physicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture. The news release said the decision should be based on a discussion of patient preferences; fracture risk profile; and the benefits, harms, and costs of medications.